Jennifer L Ridgeway1, Gladys B Asiedu1, Katherine Carroll1, Meaghan Tenney2, Aminah Jatoi3, Carmen Radecki Breitkopf4. 1. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and the Department of Health Sciences Research, Mayo Clinic, Rochester, USA. 2. Department of Obstetrics and Gynecology, The University of Chicago Medicine, Chicago, USA. 3. Department of Oncology, Mayo Clinic, Rochester, USA. 4. Department of Health Sciences Research, Mayo Clinic, Rochester, USA. Electronic address: radeckibreitkopf.carmen@mayo.edu.
Abstract
OBJECTIVE: Clinical trials are vital in the context of ovarian cancer and may offer further treatment options during disease recurrence, yet enrollment remains low. Understanding patient and family member experiences with identifying trials can inform engagement and education efforts. METHODS: Interviews were conducted with 33 patients who had experience with clinical trial conversations and 39 nominated family members. Thematic analysis examined experiences and generated findings for clinical practice. RESULTS: Trial conversations with providers at diagnosis were uncommon and often overwhelming. Most participants delayed engagement until later in the disease course. With hindsight, though, some wished they considered trials earlier. Difficulty identifying appropriate trials led some to defer searching to providers, but then they worried about missed opportunities. Most family members felt unqualified to search. CONCLUSION: Trial conversations during clinical encounters should start early and include specifying search responsibilities of providers, patients, and family. Patients and family members can be engaged in searches but need guidance. PRACTICE IMPLICATIONS: Trials should be discussed throughout the disease course, even if patients are not ready to participate or are not making a treatment decision. Education should focus on identifying trials that meet search criteria. Transparency regarding each individual's role in identifying trials is critical.
OBJECTIVE: Clinical trials are vital in the context of ovarian cancer and may offer further treatment options during disease recurrence, yet enrollment remains low. Understanding patient and family member experiences with identifying trials can inform engagement and education efforts. METHODS: Interviews were conducted with 33 patients who had experience with clinical trial conversations and 39 nominated family members. Thematic analysis examined experiences and generated findings for clinical practice. RESULTS: Trial conversations with providers at diagnosis were uncommon and often overwhelming. Most participants delayed engagement until later in the disease course. With hindsight, though, some wished they considered trials earlier. Difficulty identifying appropriate trials led some to defer searching to providers, but then they worried about missed opportunities. Most family members felt unqualified to search. CONCLUSION: Trial conversations during clinical encounters should start early and include specifying search responsibilities of providers, patients, and family. Patients and family members can be engaged in searches but need guidance. PRACTICE IMPLICATIONS: Trials should be discussed throughout the disease course, even if patients are not ready to participate or are not making a treatment decision. Education should focus on identifying trials that meet search criteria. Transparency regarding each individual's role in identifying trials is critical.
Authors: Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: E Y N Yuen; S Dodson; R W Batterham; T Knight; J Chirgwin; P M Livingston Journal: Eur J Cancer Care (Engl) Date: 2015-01-29 Impact factor: 2.520
Authors: LaPrincess C Brewer; Sharonne N Hayes; Monica W Parker; Joyce E Balls-Berry; Michele Y Halyard; Vivian W Pinn; Carmen Radecki Breitkopf Journal: J Womens Health (Larchmt) Date: 2014-07-21 Impact factor: 2.681
Authors: Margo Michaels; Thomas A D'Agostino; Natasha Blakeney; Elisa S Weiss; Maria C Binz-Scharf; Mitch Golant; Carma L Bylund Journal: J Cancer Educ Date: 2015-03 Impact factor: 2.037
Authors: H A Tejeda; S B Green; E L Trimble; L Ford; J L High; R S Ungerleider; M A Friedman; O W Brawley Journal: J Natl Cancer Inst Date: 1996-06-19 Impact factor: 13.506
Authors: William R Robinson; Joyce Ritter; April S Rogers; Sean Tedjarati; Christy Lieberenz Journal: Int J Gynecol Cancer Date: 2009-01 Impact factor: 3.437
Authors: Gladys B Asiedu; Jennifer L Ridgeway; Katherine Carroll; Aminah Jatoi; Carmen Radecki Breitkopf Journal: Health Expect Date: 2018-04-14 Impact factor: 3.377
Authors: Dinesh Pal Mudaranthakam; Alexander M Alsup; Vinay Murakonda; Tara Lin; Jeffrey Thompson; Byron Gajewski; Matthew S Mayo Journal: Cancer Inform Date: 2022-01-25